W. Muntean

4.8k total citations
150 papers, 3.3k citations indexed

About

W. Muntean is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, W. Muntean has authored 150 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Hematology, 25 papers in Pulmonary and Respiratory Medicine and 19 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in W. Muntean's work include Blood Coagulation and Thrombosis Mechanisms (83 papers), Platelet Disorders and Treatments (43 papers) and Hemophilia Treatment and Research (35 papers). W. Muntean is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (83 papers), Platelet Disorders and Treatments (43 papers) and Hemophilia Treatment and Research (35 papers). W. Muntean collaborates with scholars based in Austria, Germany and United States. W. Muntean's co-authors include Bettina Leschnik, Siegfried Gallistl, Gerhard Cvirn, Siegfried Gallistl, Werner Zenz, G Zobel, Karl Sudi, Martin Borkenstein, H. M. Grubbauer and Harald Haidl and has published in prestigious journals such as New England Journal of Medicine, Blood and PEDIATRICS.

In The Last Decade

W. Muntean

147 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Muntean Austria 31 2.0k 577 574 494 409 150 3.3k
Janna M. Journeycake United States 22 1.3k 0.7× 484 0.8× 941 1.6× 601 1.2× 316 0.8× 70 2.3k
Gili Kenet Israel 37 4.1k 2.0× 566 1.0× 1.1k 1.9× 601 1.2× 405 1.0× 223 5.5k
Lesley Mitchell Canada 42 3.2k 1.6× 1.2k 2.1× 2.3k 4.1× 1.1k 2.2× 671 1.6× 119 5.2k
Pearl Toy United States 33 806 0.4× 213 0.4× 155 0.3× 391 0.8× 467 1.1× 93 4.2k
Jun Teruya United States 24 571 0.3× 523 0.9× 282 0.5× 531 1.1× 202 0.5× 124 2.3k
Angelo Claudio Molinari Italy 26 1.4k 0.7× 119 0.2× 253 0.4× 310 0.6× 211 0.5× 103 2.1k
Rasheed A. Balogun United States 23 987 0.5× 306 0.5× 67 0.1× 662 1.3× 433 1.1× 67 3.8k
Herbert Schöchl Austria 45 1.1k 0.5× 583 1.0× 660 1.1× 1.7k 3.4× 715 1.7× 148 6.9k
Rezan A. Kadir United Kingdom 46 3.2k 1.5× 523 0.9× 423 0.7× 738 1.5× 289 0.7× 163 6.3k
Vesa Rasi Finland 25 750 0.4× 274 0.5× 176 0.3× 262 0.5× 508 1.2× 77 2.8k

Countries citing papers authored by W. Muntean

Since Specialization
Citations

This map shows the geographic impact of W. Muntean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Muntean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Muntean more than expected).

Fields of papers citing papers by W. Muntean

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Muntean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Muntean. The network helps show where W. Muntean may publish in the future.

Co-authorship network of co-authors of W. Muntean

This figure shows the co-authorship network connecting the top 25 collaborators of W. Muntean. A scholar is included among the top collaborators of W. Muntean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Muntean. W. Muntean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pabinger, Ingrid, et al.. (2015). Hämophiliebehandlung in Österreich. Wiener klinische Wochenschrift. 127(S3). 115–130. 7 indexed citations
3.
Gouw, Samantha C., Johanna G. van der Bom, Rolf Ljung, et al.. (2013). Factor VIII Products and Inhibitor Development in Severe Hemophilia A. New England Journal of Medicine. 368(3). 231–239. 304 indexed citations
4.
Schlagenhauf, Axel, et al.. (2012). Thrombin receptor levels in platelet concentrates during storage and their impact on platelet functionality. Transfusion. 52(6). 1253–1259. 16 indexed citations
5.
Streif, Werner, et al.. (2009). Österreichisches Hämophilie Register. Hämostaseologie. 29. 13–15. 2 indexed citations
6.
Vcelar, Brigitta, Gabriela Stiegler, Hermann M. Wolf, et al.. (2007). Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS. 21(16). 2161–2170. 42 indexed citations
7.
Köestenberger, Martin, et al.. (2006). The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT. Thrombosis Research. 119(3). 361–367. 11 indexed citations
8.
Cvirn, Gerhard, et al.. (2005). Higher Concentrations of Heparin and Hirudin Are Required to Inhibit Thrombin Generation in Tissue Factor–Activated Cord Plasma Than in Adult Plasma. Pediatric Research. 57(5 Part 1). 685–689. 13 indexed citations
9.
Gallistl, Siegfried, Martin Köestenberger, Peter Fritsch, et al.. (2004). The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin α activated): comparison between cord and adult plasma. Thrombosis and Haemostasis. 91(5). 912–918. 10 indexed citations
10.
Beitzke, A, Andreas Gamillscheg, Karl Sudi, et al.. (2003). Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover. Thrombosis Research. 111(6). 335–341. 8 indexed citations
11.
Gallistl, Siegfried, Gerhard Cvirn, Bettina Leschnik, & W. Muntean. (2002). Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagulation & Fibrinolysis. 13(7). 653–655. 16 indexed citations
12.
Zenz, Werner, et al.. (2001). Danaparoid sodium (Orgaran®) in four children with heparin‐induced thrombocytopenia type II. Acta Paediatrica. 90(7). 765–771. 25 indexed citations
13.
Muntean, W., et al.. (1997). Longer aPTT Values in Healthy Children than in Adults: No Single Cause. Thrombosis Research. 88(4). 355–359. 18 indexed citations
14.
Fauler, Günter, et al.. (1996). Method for the Determination of Vitamin K1(20)in Human Plasma by Stable Isotope Dilution/Gas Chromatography/Mass Spectrometry. Journal of Mass Spectrometry. 31(6). 655–660. 19 indexed citations
15.
Muntean, W. & Bettina Leschnik. (1989). Factor VIII influences binding of factor IX and factor X to intact human platelets. Thrombosis Research. 55(5). 537–548. 4 indexed citations
16.
Schimpf, K., H.H. Brackmann, W. Kreuz, et al.. (1989). Absence of Anti-Human Immunodeficiency Virus Types 1 and 2 Seroconversion after the Treatment of Hemophilia A or von Willebrand's Disease with Pasteurized Factor VIII Concentrate. New England Journal of Medicine. 321(17). 1148–1152. 53 indexed citations
17.
Muntean, W., Bettina Leschnik, & Josef Haas. (1987). Factor VIII coagulant moiety binds to platelets by binding to phospholipids of the platelet membrane. Thrombosis Research. 45(4). 345–354. 8 indexed citations
18.
Borkenstein, Martin, W. Muntean, & E. Ott. (1984). Elevated plasma fibronectin is associated with increased blood viscosity and red cell aggregation in diabetic children. Pediatric Research. 18(11). 1219–1219. 1 indexed citations
19.
Muntean, W.. (1983). [Vitamin K deficiency in the newborn].. PubMed. 95(1). 1–5. 2 indexed citations
20.
Borkenstein, Martin & W. Muntean. (1982). Elevated factor VIII activity and factor VIII-related antigen in diabetic children without vascular disease. Diabetes. 31(11). 1006–1009. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janna M. Journeycake Breakdown of academic impact, for papers by Gili Kenet Breakdown of academic impact, for papers by Lesley Mitchell Breakdown of academic impact, for papers by Pearl Toy Breakdown of academic impact, for papers by Jun Teruya Breakdown of academic impact, for papers by Angelo Claudio Molinari Breakdown of academic impact, for papers by Rasheed A. Balogun Breakdown of academic impact, for papers by Herbert Schöchl Breakdown of academic impact, for papers by Rezan A. Kadir Breakdown of academic impact, for papers by Vesa Rasi
Rankless by CCL
2026